Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 8/20 | 0.36 |
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228377 | 0.87 | HTR2C (0.49) | HTR2CTNKS2TNKSSRCHTR2B | |
| SCHEMBL7162502 | 0.80 | HTR2C (0.46) | HTR2CTNKS2TNKSHTR2BHTR2A | |
| SCHEMBL25431342 | 0.80 | HPGD (0.41) | HTR2CTNKS2TNKSHPGDPOLB | |
| SCHEMBL18711813 | 0.78 | HPGD (0.54) | HTR2CSRCL3MBTL1TP53HPGD | |
| SCHEMBL12050029 | 0.78 | POLB (0.52) | HPGDPOLBALDH1A1 | |
| SCHEMBL23642016 | 0.76 | PDCD1 (0.40) | HTR2CHTR2BHTR2A | |
| SCHEMBL31351621 | 0.75 | HTR2C (0.63) | HTR2CTNKS2TNKSHTR2BHTR2A | |
| SCHEMBL31128672 | 0.73 | TNKS2 (0.54) | TNKS2TNKSPARP1 | |
| SCHEMBL7783296 | 0.73 | PARP1 (0.65) | HTR2CTNKS2TNKSSRCL3MBTL1 | |
| SCHEMBL23972783 | 0.72 | HTR2C (0.56) | HTR2CTNKS2TNKSPOLBPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024173343-A1 | COMPOUNDS TARGETING HYDROXYSTEROID 17-BETA DEHYDROGENASE (HSD17B) AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-1001970-B1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER (US) | 2007-03-07 | — | — | EP | disclosed |
| US-6953791-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-6951850-B2 | Dipeptide derivatives | PFIZER, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-6924280-B2 | Dipeptide derivatives | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-RE38524-E1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2004-06-01 | — | — | US | disclosed |
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | CARPINO PHILIP ALBERT (US) | 2004-01-15 | — | — | US | disclosed |
| US-20040006063-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2004-01-08 | — | — | US | disclosed |
| US-20030216399-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2003-11-20 | — | — | US | disclosed |
| US-6525047-B2 | Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair | PFIZER INC. | 2003-02-25 | — | — | US | disclosed |
| US-6432945-B1 | Dipeptide derivatives | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-6433171-B1 | FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS | PFIZER INC. | 2002-08-13 | — | — | US | disclosed |
| US-6429313-B2 | Dipeptide derivatives | PFIZER INC. | 2002-08-06 | — | — | US | disclosed |
| US-20020042415-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2002-04-11 | — | — | US | disclosed |
| US-20010041703-A1 | Dipeptide derivatives | CARPINO PHILIP ALBERT (US) | 2001-11-15 | — | — | US | disclosed |
| US-6251902-B1 | Dipeptide derivatives as growth hormone secretagogues | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009984-A1 | Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure | GHSR, GHRHR, GIPR | HTR2C 992/4885TNKS2 4334/4885TNKS 4665/4885 |
| US-20020042415-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | HTR2C 1093/4885TNKS2 4190/4885TNKS 4355/4885 |
| US-20010041703-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | HTR2C 2168/4885TNKS2 4150/4885TNKS 4341/4885 |
| US-20040006063-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | HTR2C 1264/4885TNKS2 4118/4885TNKS 4287/4885 |
| US-20030216399-A1 | Dipeptide derivatives | GIPR, GHRHR, GHSR | HTR2C 1093/4885TNKS2 4190/4885TNKS 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.